MBX Biosciences, Inc. MBX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about MBX Biosciences, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MBX Biosciences, Inc.'s change in accrued liabilities?
- MBX Biosciences, Inc. (MBX) reported change in accrued liabilities of -$4.86M in Q1 2026.
- How has MBX Biosciences, Inc.'s change in accrued liabilities changed year-over-year?
- MBX Biosciences, Inc.'s change in accrued liabilities decreased by 970.4% year-over-year, from $558K to -$4.86M.
- What is the long-term trend for MBX Biosciences, Inc.'s change in accrued liabilities?
- Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s change in accrued liabilities has grown at a 1151.6% compound annual growth rate (CAGR), from $45K to $7.05M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.